Estimating and validating disability-adjusted life years at the global level: a methodological framework for cancer

[1] Ferlay J(2010)Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 Int J Cancer 127 2893-2917

[2] Shin HR(2007)Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995–99: results of the EUROCARE-4 study Lancet Oncol 8 773-783

[3] Bray F(1994)Quantifying the burden of disease: the technical basis for disability-adjusted life years Bull World Health Organ 72 429-445

[4] Forman D(2007)Estimating and modeling the cure fraction in population-based cancer survival analysis Biostatistics 8 576-594

[5] Mathers C(1999)Estimates of the worldwide mortality from 25 cancers in 1990 Int J Cancer 83 18-29

[6] Parkin DM(2011)The validity of the mortality to incidence ratio as a proxy for site-specific cancer survival Eur J Public Health 21 573-577

[7] Berrino F(2008)Superior survival of females among 10,538 Dutch melanoma patients is independent of Breslow thickness, histologic type and tumor site Ann Oncol 19 583-589

[8] De Angelis R(2010)Regional trends in prostate cancer incidence, treatment with curative intent and mortality in Norway 1980–2007 Cancer Epidemiol 34 359-367

[9] Sant M(2009)Time, symptom burden, androgen deprivation, and self-assessed quality of life after radical prostatectomy or watchful waiting: the Randomized Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) clinical trial Eur Urol 55 422-430

[10] Rosso S(2005)Paternity following treatment for testicular cancer J Natl Cancer Inst 97 1580-1588

[1] Ferlay J(2010)Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 Int J Cancer 127 2893-2917

[2] Shin HR(2007)Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995–99: results of the EUROCARE-4 study Lancet Oncol 8 773-783

[3] Bray F(1994)Quantifying the burden of disease: the technical basis for disability-adjusted life years Bull World Health Organ 72 429-445

[4] Forman D(2007)Estimating and modeling the cure fraction in population-based cancer survival analysis Biostatistics 8 576-594

[5] Mathers C(1999)Estimates of the worldwide mortality from 25 cancers in 1990 Int J Cancer 83 18-29

[6] Parkin DM(2011)The validity of the mortality to incidence ratio as a proxy for site-specific cancer survival Eur J Public Health 21 573-577

[7] Berrino F(2008)Superior survival of females among 10,538 Dutch melanoma patients is independent of Breslow thickness, histologic type and tumor site Ann Oncol 19 583-589

[8] De Angelis R(2010)Regional trends in prostate cancer incidence, treatment with curative intent and mortality in Norway 1980–2007 Cancer Epidemiol 34 359-367

[9] Sant M(2009)Time, symptom burden, androgen deprivation, and self-assessed quality of life after radical prostatectomy or watchful waiting: the Randomized Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) clinical trial Eur Urol 55 422-430

[10] Rosso S(2005)Paternity following treatment for testicular cancer J Natl Cancer Inst 97 1580-1588